The Department of Health and Human Services today announced that later this week it will distribute $9 billion of the $17 billion in Provider Relief Fund “Phase 4” payments to providers who have experienced revenue losses and expenses related to the COVID-19 pandemic. In addition, HHS stated that it is currently reviewing the remaining Phase 4 applications and will make the remainder of Phase 4 payments in 2022. 

In today’s announcement, HHS stated that more than 69,000 providers will receive Phase 4 payments beginning Dec. 16. The average payment for small providers is $58,000, for medium providers $289,000, and for large providers $1.7 million. The Health Resources and Services Administration processed approximately 75% of Phase 4 applications; remaining Phase 4 applications require additional review, and HRSA will make the remainder of the payments next year. 

Consistent with the Phase 4 payment methodology released by HRSA in September, approximately 75% of Phase 4 funding is being distributed based on expenses and decreased revenue from July 1, 2020 to March 31, 2021. Smaller providers will be reimbursed at a higher percentage of losses and expenses as compared to larger providers. The remaining 25% of Phase 4 funding is being distributed as “bonus” payments based on the amount and type of services provided to Medicare, Medicaid or Children’s Health Insurance Program patients. HRSA is using Medicare reimbursement rates in calculating these payments. 
 

Related News Articles

Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…